Kura Oncology, Inc. (KURA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 12.13 |
| Open | 12.39 |
| Bid | 10.10 x 1300 |
| Ask | 19.63 x 800 |
| Day's Range | 11.90 - 12.81 |
| 52 Week Range | 10.41 - 24.36 |
| Volume | |
| Avg. Volume | 628,640 |
| Market Cap | 837.938M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.92 |
| Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.88 |
- GlobeNewswire
Kura Oncology Reports First Quarter 2022 Financial Results
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patient in HRAS overexpression cohort expected by third quarter – – First patient in Phase 1 KURRENT-LUNG trial of tipifarnib plus osimertinib expected in third quarter – – $480 million in cash, cash equivalents and investments provide runway
- GlobeNewswire
Kura Oncology to Report First Quarter 2022 Financial Results
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a c
- GlobeNewswire
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – – Company to initiate clinical trial of tipifarnib in combination with osimertinib in NSCLC in the third quarter of 2022 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, remains on track for submission in the fourth quarter of 2022 – SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Kur
